Results 221 to 230 of about 16,466 (254)
Some of the next articles are maybe not open access.
Journal of the American Academy of Dermatology, 1997
Oral terbinafine was first introduced in the United Kingdom in February 1991 and was approved for the treatment of onychomycosis in the United States in May 1996. It is estimated that 4 million patients worldwide have been treated with oral terbinafine as of December 1996.
Neil H. Shear, Aditya K. Gupta
openaire +3 more sources
Oral terbinafine was first introduced in the United Kingdom in February 1991 and was approved for the treatment of onychomycosis in the United States in May 1996. It is estimated that 4 million patients worldwide have been treated with oral terbinafine as of December 1996.
Neil H. Shear, Aditya K. Gupta
openaire +3 more sources
Determination of terbinafine in tissues
Biomedical Chromatography, 2000Terbinafine and N-demethyl terbinafine concentrations were determined simultaneously in rat tissues by a high-performance liquid chromatography method. This method involved the homogenization of tissues (except for skin) followed by a liquid-liquid extraction. Skin samples were dissolved in sodium hydroxide prior to extraction.
Mahboubeh Hosseini Yeganeh +1 more
openaire +3 more sources
Terbinafine-Associated Hepatotoxicity
The American Journal of the Medical Sciences, 2003Terbinafine, an orally and topically active agent licensed for treatment of dermatophytic infection, has gained rapid worldwide acceptance in medical practice. Despite its fairly benign profile of adverse reactions, liver toxicity has occasionally been linked to terbinafine.
Challa Ajit +3 more
openaire +3 more sources
Treatment of onychomycosis with terbinafine
British Journal of Dermatology, 1992An open multicentre trial was conducted by 40 dermatologists in Switzerland involving 188 patients with onychomycosis of either the toenails or fingernails. Of these patients, 145 who had positive microscopy and culture of dermatophyte infection were evaluable: of the dermatophytes identified at the initial visit, 80% were Trichophyton rubrum and 12.4%
P.B. Wili +3 more
openaire +3 more sources
Chemical Research in Toxicology, 2001
Oral terbinafine treatment for superficial fungal infections of toe and fingernails is associated with a low incidence (1:45000) of hepatobiliary dysfunction. Due to the rare and unpredictable nature of this adverse drug reaction, the mechanism of toxicity has been hypothesized to be either an uncommon immunological or metabolically mediated effect ...
Suzanne L. Iverson, Jack Uetrecht
openaire +3 more sources
Oral terbinafine treatment for superficial fungal infections of toe and fingernails is associated with a low incidence (1:45000) of hepatobiliary dysfunction. Due to the rare and unpredictable nature of this adverse drug reaction, the mechanism of toxicity has been hypothesized to be either an uncommon immunological or metabolically mediated effect ...
Suzanne L. Iverson, Jack Uetrecht
openaire +3 more sources
Der Hautarzt, 2016
The allylamine terbinafine is the probably most frequently prescribed systemic antifungal agent in Germany for the treatment of dermatomycoses and onychomycoses. According to the German drug law, terbinafine is approved for patients who are 18 years and older; however, this antifungal agent is increasingly used off-label for treatment of onychomycoses ...
A. Dürrbeck, P. Nenoff
openaire +4 more sources
The allylamine terbinafine is the probably most frequently prescribed systemic antifungal agent in Germany for the treatment of dermatomycoses and onychomycoses. According to the German drug law, terbinafine is approved for patients who are 18 years and older; however, this antifungal agent is increasingly used off-label for treatment of onychomycoses ...
A. Dürrbeck, P. Nenoff
openaire +4 more sources
Terbinafine-induced liver injury
The National Medical Journal of India, 2017Terbinafine is a common antifungal agent with few reports of liver injury. We present a 64-year-old man who developed terbinafine-induced liver injury. Drug-induced liver injury is an important cause of morbidity and an early diagnosis may prevent progression to severe and chronic forms of liver injury including fulminant hepatic failure.
Shiwani Sharma +3 more
openaire +3 more sources
2003
Abstract Terbinafine is a newly developed oral and topical antifungal agent in the allylamine class of antifungal compounds (Petranyi et al, 1984). Discovered in 1983, it is closely related to naftifine. Terbinafine became available in Europe in 1991, and in 1996 in the United States.
openaire +1 more source
Abstract Terbinafine is a newly developed oral and topical antifungal agent in the allylamine class of antifungal compounds (Petranyi et al, 1984). Discovered in 1983, it is closely related to naftifine. Terbinafine became available in Europe in 1991, and in 1996 in the United States.
openaire +1 more source
Terbinafine-induced hepatic dysfunction
European Journal of Gastroenterology & Hepatology, 2001A 41-year-old man developed severe hepatic dysfunction following a 3.5-week course of terbinafine (250 mg/day). He suffered marked pruritus, jaundice, malaise, anorexia and loin pain. Serum bilirubin rose to a peak value of 718 micromol/l with alkaline phosphatase at 569 U/l, alanine aminotransferase at 90 U/l, aspartate aminotransferase at 63 U/l and ...
William M. Chambers +3 more
openaire +2 more sources
The efficacy and safety of terbinafine in children
Journal of the European Academy of Dermatology and Venereology, 2003ABSTRACTTerbinafine is an allylamine antifungal agent that has been effective and safe in the treatment of superficial and some deep mycotic infections in adults. An increasing amount of data is available where terbinafine has been used in the paediatric population to treat superficial fungal infections, in particular tinea capitis.
Elizabeth A. Cooper +2 more
openaire +5 more sources